Transcript
A (0:00)
Foreign It's March 24, 2026 and this is a commerce rift brought to you by the CPG guys. 10 minutes of the news stories that matter most in commerce this week. I'm your co host, pvsb and I'm joined by Papa Raj, the father of Pop stars, CO founder and CRO of Think Blue Consulting. Sree, how's the SoCal heat wave going?
B (0:20)
You know what I'm looking forward to? The heat wave actually came to a shocking end this morning. So in usual Sunday fashion, I was out with Bala our dog and I wore shorts and a T shirt, as you can see, and the chill went through my spine. It's a whopping 48 degrees. You know, in the Valley here, even in the hottest days before 10am it's actually pretty chilly, but temperature drops to 73. But you know what I'm looking forward to this week? Las Vegas and Shop Talk. At the time of this recording, we'd already be a day and a half in looking forward to all the dinners we're hosting, all the podcasts we're doing. Should be a great week, great event. Peter, what do you have for us today?
A (0:54)
Sree, I hope that Giants T shirt you're wearing is not symbolic of the fact that you've given up on the Yankees and the season hasn't even started yet. I know that's not the case, Shree. It's a new baseball season coming our way very shortly. First story the cost of GLP1 drugs is falling and pill versions are hitting the US market. For restaurant chains and snacking giants, higher adoption of weight loss and diabetes treatments poses a threat to their sales or an opportunity. GLP1 drugs slow digestion, suppress user appetites, and increase satiety. For many restaurants and packaged goods manufacturers, those reactions will likely mean weaker sales. Adults who use GLP1s consume 21% fewer calories and spend nearly a third less on grocery bills on average, according to kpmg. JP Morgan estimates the growing use of the medications could wipe out ready for this Sri $30 billion to $55 billion in annual sales for the food and be industry as soon as 2030. About one in every eight US adults is currently taking a GLP1 drug like Ozempic or Zepbound, according to the KFF Health Tracking poll conducted last fall. The number doesn't include consumers who have discontinued rather their use of the drug. 18% of respondents said that they have taken a GLP1 medication at some point. Those numbers are expected to keep climbing, especially after Novo Nordisk launches its Wegovy pill in January, and Eli Lilly prepares to roll out its own oral drug this year. By 2030, more than 30 million Americans could be on a GLP1 treatment, up from 10 million in 2026, based on JP Morgan estimates. But the shift also presents an opportunity for restaurants and food and beverage companies with new protein and fiber options. Many businesses are hoping to win over GLP1 Consumers and mollify investors concerns about how the treatment will affect their bottom lines. Whether it's labeling as GLP1 friendly, increasing the serving size, emphasizing protein content, or even when you shift over to the beverage world because hydration is certainly a concern, there are a number of players that are starting to react to this, said Don K. Johnson, Principle of strategy and execution for EY Parthenon. About half of GLP1 users report consuming fewer calories while taking the medications, according to UBS Evidence Lab. But the effects aren't even across the industry, and certain categories are more impacted than others, Johnson said. Snacking, once one of the fastest growing grocery segments, has taken the biggest hit. About 70% of GLP1 users who report consuming fewer calories said that they are snacking less, according to a survey conducted by E.Y. parthenon last spring. Quote I think it's about have about the specific type of snack, but I do think they're also snacking less. Having said that, we do see that there's a shift to healthier foods and that certainly will include healthier snacking. Unquote, johnson said. Think more yogurt, nuts or fruit and fewer chips or pretzels. SRI over to you.
